Get the Stockscreener App
45.21
2.54%
-1.18
After Hours:
45.21
Janux Therapeutics Inc Stock (JANX) Latest News
Vestal Point Capital LP Sells 240,000 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Algert Global LLC Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Ally Bridge Group NY LLC Invests $4.94 Million in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics CEO David Campbell sells $1.3 million in stock - Investing.com
How Are Things Looking For Janux Therapeutics Inc (NASDAQ: JANX) For The Short Term? - Stocks Register
Victory Capital Management Inc. Raises Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Victory Capital Management Inc. Grows Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Janux to Present JANX007 Phase 1a Clinical Data for Prostate Cancer Treatment | JANX Stock News - StockTitan
Janux Therapeutics initiated with an Outperform at Leerink - MSN
Leerink Partnrs Upgrades Janux Therapeutics (NASDAQ:JANX) to Strong-Buy - Defense World
Leerink Partners Initiates Coverage on Janux Therapeutics (NASDAQ:JANX) - Defense World
Objective long/short (JANX) Report - Stock Traders Daily
Janux Therapeutics (NASDAQ:JANX) Upgraded to "Strong-Buy" at Leerink Partnrs - MarketBeat
Leerink Partners Initiates Coverage of Janux Therapeutics (JANX) with Outperform Recommendation - MSN
Leerink sets shares target on Janux Therapeutics, cites platform By Investing.com - Investing.com Canada
Evaluating Janux Therapeutics: Insights From 6 Financial Analysts - Benzinga
Janux Therapeutics’ Q3 Report: Financials and Progress - TipRanks
Stifel Initiates Coverage of Janux Therapeutics (JANX) with Buy Recommendation - MSN
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation - Seeking Alpha
Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors - MSN
Citadel Advisors LLC Adjusts Stake in Janux Therapeutics Inc - GuruFocus.com
Long Term Trading Analysis for (JANX) - Stock Traders Daily
FMR LLC's Strategic Acquisition of Janux Therapeutics Shares - GuruFocus.com
William Blair Predicts Lower Earnings for Janux Therapeutics - Defense World
HC Wainwright Has Negative Outlook of JANX FY2024 Earnings - Defense World
Janux Therapeutics’ (JANX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
What is HC Wainwright's Forecast for JANX FY2024 Earnings? - MarketBeat
William Blair Issues Pessimistic Forecast for JANX Earnings - MarketBeat
Janux Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Janux Therapeutics earnings missed by $0.18, revenue fell short of estimates - Investing.com UK
Janux Therapeutics price target raised to $82 from $62 at BTIG - TipRanks
Janux Therapeutics Cash Soars to $658M Despite Widening Q3 Losses; Trial Updates Ahead | JANX Stock News - StockTitan
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
Nisa Investment Advisors LLC Has $924,000 Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Stock Price Up 6.3%Here's Why - MarketBeat
10 Best-Performing Stocks in 2024 - Markets.com
How to Take Advantage of moves in (JANX) - Stock Traders Daily
Bath & Body Works, Paramount Global, and More Stocks See Action From Activist Investors - Barron's
Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) Price Target at $66.44 - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Janux Therapeutics CEO sells shares worth $1.34 million By Investing.com - Investing.com Australia
Janux Therapeutics CEO sells shares worth $1.34 million - Investing.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - MarketBeat
This Insider Has Just Sold Shares In Janux Therapeutics - Simply Wall St
Warren Buffett Back for More, Plus Big Insider Buying at Biotechs Too - 24/7 Wall St.
Janux Therapeutics (NASDAQ:JANX) Coverage Initiated at UBS Group - Defense World
Keros Therapeutics (NASDAQ:KROS) Now Covered by Cantor Fitzgerald - Defense World
UBS Initiates Coverage of Janux Therapeutics (JANX) with Buy Recommendation - MSN
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):